Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving cisplatin and paclitaxel together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin and paclitaxel together with everolimus and to see how well it works in treating patients with metastatic breast cancer.

Key facts

Study ID

NCT01031446

Run by

Vanderbilt-Ingram Cancer Center

People needed

55

Starts

2009-10-01

Expected to finish

2017-08-01

Last updated by the study team

2018-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Erlanger Cancer Center at Erlanger Hospital - Baroness — Chattanooga, Tennessee, United States
• West Tennessee Cancer Center at Jackson-Madison County General Hospital — Jackson, Tennessee, United States
• Baptist Regional Cancer Center at Baptist Riverside — Knoxville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.